NSE: SUNPHARMA | BSE: 524715

Mid-range Performer

Download real time

1580.30 -20.00 (-1.25%)

Near 52W Low of ₹1553.05

3.0M NSE+BSE Volume

NSE 28 Aug, 2025 1:16 PM (IST)

379,166.9

Market Cap

Market Leader

0.6

Beta 1Year

Very Low volatility

Sun Pharmaceutical Industries Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for SUNPHARMA, BSE:524715 Sun Pharmaceutical Industries Ltd.

Search Inside the pdf :

Sun Pharmaceutical Industries Ltd.

05 Aug 2025

1580.30

-1.25%

SUN PHARMA

Buy: Sun Pharmaceutical Industr...

Recommendation Target

Geojit BNP Paribas

Sun Pharma performed resiliently, driven by strong prescription momentum in India, *over or under performance to benchmark index strategic rural field force expansion and focused execution in its US specialty business. The management is actively steering pipeline progression with regulatory filings across key therapy areas backed by sustained research and development intensity. The company maintains a calibrated stance on US manufacturing, given adequate capacity and exemption from the current tariff measures. Notably, its firstmover positioning in India's GLP-1 space and accelerated launch of readiness for...

Sun Pharmaceutical Industries Ltd. is trading below all available SMAs

Sun Pharmaceutical Industries Ltd.

01 Aug 2025

1580.30

-1.25%

Sun Pharmaceutical Industries (SUNP IN) Q1FY26 Result Update ...

Buy: Sun Pharmaceutical Industr...

Target

Prabhudas Lilladhar

Reiterate its $100mn expenses towards new launches of specialty in FY26. Sun Pharma (SUNP) Q1FY26 EBIDTA (+11% YoY) was 7% above our estimates aided by higher specialty sales and lower opex. Over last few years SUNP dependency on US generics has reduced and company's growth is more functional on specialty, RoW and domestic pharma that has strong growth visibility. Though FY26 expenses (an additional $100mn spend) is likely to remain elevated given company are in investment phase to ramp up specialty...

Sun Pharmaceutical Industries Ltd. is trading below all available SMAs

Sun Pharmaceutical Industries Ltd.

31 Jul 2025

1580.30

-1.25%

Innovative/branded portfolio drives earnings

Buy: Sun Pharmaceutical Industr...

Target

Motilal Oswal

Sun Pharmaceutical Industries’ (SUNP) 1QFY26 revenue and EBITDA were 3%/9% better than our estimates. However, Adj. PAT was lower than expected (6% miss) due to lower other income and a higher tax rate.

Sun Pharmaceutical I.. has an average target of 2050.25 from 8 brokers.

Sun Pharmaceutical Industries Ltd.

23 May 2025

1580.30

-1.25%

Sun Pharma (BUY): Specialty launches to contribute 20% of global specialty sales

Buy: Sun Pharmaceutical Industr...

Target

BOB Capital Markets Ltd.

Sales/EBITDA/APAT were lower than our estimates by 3.5%/9.6%/29.4%. ETR for 4QFY25 stood at 32.9% including 1x tax expense of Rs 3.7bn

Sun Pharmaceutical I.. has an average target of 2050.25 from 8 brokers.

Sun Pharmaceutical Industries Ltd.

23 May 2025

1580.30

-1.25%

India/EM outperformers; US/ROW underperformers

Buy: Sun Pharmaceutical Industr...

Target

Motilal Oswal

Sun Pharmaceutical Industries (SUNP) delivered 4%/9%/4% miss on revenue/EBITDA/PAT for 4QFY25. Lower-than-expected sales in global specialty and ROW led to a miss on 4QFY25 performance.

Number of FII/FPI investors decreased from 1351 to 1326 in Jun 2025 qtr

Sun Pharmaceutical Industries Ltd.

23 May 2025

1580.30

-1.25%

Sun Pharmaceutical Industries (SUNP IN) Q4FY25 Result Update ...

Buy: Sun Pharmaceutical Industr...

Target

Prabhudas Lilladhar

Sun Pharma (SUNP) Q4FY25 EBIDTA (+11% YoY) was largely in line however moderate growth (9% YoY) in specialty sales after several quarters of strong double-digit growth was below our estimate. Over last few years SUNP dependency on US generics has reduced and company's growth is more functional on specialty, RoW and domestic pharma that has strong growth visibility. Though FY26 expenses (an additional $100mn spend) is likely to remain elevated given company are in investment phase to ramp up specialty...

Number of FII/FPI investors decreased from 1351 to 1326 in Jun 2025 qtr

Sun Pharmaceutical Industries Ltd.

10 Apr 2025

1580.30

-1.25%

Order vacating injunction on Leqselvi a material positive

Buy: Sun Pharmaceutical Industr...

Emkay

The US Court of Appeals has vacated the preliminary injunction against Sun Pharma’s launch of Leqselvi which was granted by the US District Court of New Jersey in Nov-24.

Number of FII/FPI investors decreased from 1351 to 1326 in Jun 2025 qtr

Sun Pharmaceutical Industries Ltd.

11 Mar 2025

1580.30

-1.25%

On a spree to expand specialty portfolio

Buy: Sun Pharmaceutical Industr...

Recommendation Target

ICICI Securities Limited

Sun Pharma (Sun) is acquiring US-based early-stage oncology-focused biotech company Checkpoint Therapeutics (Checkpoint) for an upfront cash payment of USD 4.1/share (total outgo of USD 355mn) and USD 0.7/share in cash in future milestones.